project id: TCGA-TGCT; case submitter id: TCGA-2G-AAFI; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.81; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.43; rna integrity number: 8.7; age at index: 41; days to birth: -14976; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1972; age at diagnosis: 14976; ajcc clinical m: M0; ajcc clinical n: N0; ajcc clinical stage: Stage IB; ajcc clinical t: T2; ajcc pathologic m: M0; ajcc pathologic n: N0; ajcc pathologic stage: Stage IB; ajcc pathologic t: T2; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 675.0; icd 10 code: C62.90; last known disease status: not reported; morphology: 9070/3; primary diagnosis: Embryonal carcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Testis, NOS; synchronous malignancy: No; tissue or organ of origin: Testis, NOS; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 237; days to sample procurement: 0; initial weight: 260.0; portion submitter id: TCGA-2G-AAFI-01A-21; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 15.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 85.0; percent tumor nuclei: 65.0;